A Russian-developed peptide pitched online as a calm-without-sedation alternative to anti-anxiety drugs. Here's what Selank actually is, what the mostly-Russian research does and doesn't show, how it's reconstituted, and exactly where it stands with the FDA in 2026.
Selank (sometimes "TP-7") is a synthetic heptapeptide — a chain of seven amino acids — developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It's a synthetic analog of tuftsin, a naturally occurring immune-modulating peptide, with a short sequence added to make it more stable. It has been studied as an anxiolytic (anti-anxiety) and nootropic agent, and is often marketed online as a "calm without sedation" peptide. It is not a vitamin, a supplement, or an FDA-approved medication.
The honest headline: the evidence is real but narrow. Selank has actual human clinical work behind it — but that work comes almost entirely from Russian research institutions, with limited independent international replication. That gap between confident online marketing and a thin, geographically concentrated evidence base is exactly what this page exists to close.
Selank is not an FDA-approved drug in the United States, and the regional picture matters:
Want the live picture? Our regulatory-status tracker shows exactly where Selank and other peptides stand right now, with the dated primary sources.
In Russian clinical research, Selank has been studied in patients with generalized anxiety disorder, neurasthenia, and cognitive complaints, with published trials reporting anxiolytic and mild cognitive effects. Proposed mechanisms include modulation of brain-derived neurotrophic factor (BDNF), serotonin systems, and the immune-signaling pathways inherited from its tuftsin parent. Researchers note it appears generally well tolerated in those studies.
The big caveat: that evidence base is predominantly Russian, with limited international validation and limited long-term safety data. Few large, independent, placebo-controlled trials exist outside that body of work, and much of what circulates online is anecdote layered on top. That doesn't mean it "doesn't work" — it means the broad, independently replicated evidence needed to say it works safely in people largely isn't there yet. Treat confident claims with skepticism.
Commonly reported doses land around 0.25–0.3 mg per dose, taken intranasally or subcutaneously. To be clear: these are not approved or standardized doses — they reflect what clinics and the wider community commonly report using today, shared for education, not medical advice. Any decision belongs with a licensed provider.
Selank typically ships as a freeze-dried (lyophilized) powder that must be reconstituted with bacteriostatic water before it's a liquid. The math — concentration and the volume to draw — trips a lot of people up, and a misplaced decimal in micrograms is a 1,000× error. That's what our free tool is for:
In the available (mostly Russian) studies, Selank is described as generally well tolerated, and — unlike benzodiazepines — that research has not reported sedation, tolerance, dependence, or a withdrawal syndrome. That's part of its appeal in the marketing. But the honest qualifier is that long-term safety in humans is simply not well established outside that narrow research setting, and independent data is limited. Product quality also varies enormously between sources: because much of the supply is research-use-only and unregulated, purity, sterility, and accurate labeling are real concerns — which is why sourcing and testing matter as much as the molecule itself.
If you're considering Selank, the responsible path runs through a licensed provider who can weigh your situation — including any existing anxiety treatment or medications — not a checkout page. Questions worth asking: Is there third-party testing and a certificate of analysis? What's the source and is it disclosed? What does the provider make of the limited, mostly-Russian evidence and the current U.S. legal status? This isn't legal or medical advice — it's the baseline diligence any unapproved substance deserves.
No. It's a peptide — a short chain of amino acids — not a benzodiazepine or any conventional anti-anxiety drug. Part of the research interest is precisely that it doesn't appear to cause the sedation, tolerance, or dependence associated with benzodiazepines, though long-term human data is limited.
It's approved in Russia for generalized anxiety disorder and used as a nootropic. It is not FDA-approved in the United States, where it's treated as a research peptide. Approval in one country is not approval everywhere.
They're different Russian-developed peptides often discussed together; Semax is more associated with cognitive and neuroprotective effects, Selank with anxiety. We cover peptides separately in the library, and the same caveats about limited international evidence apply to both.
We don't sell peptides and we don't direct consumers to buy unapproved substances. If a licensed provider determines it's appropriate, sourcing and testing should be part of that conversation.
Educational information only. Not medical, legal, or regulatory advice, not a dosing, treatment, or efficacy claim, and not a recommendation to obtain or use any substance. Many peptides are not FDA-approved; some are labeled research-use-only ("not for human use"). Regulatory status changes frequently — verify independently and consult a licensed provider before any health decision. Published by Health Pro Distributors. © 2026.